Persistent symptoms and lab abnormalities in patients who recovered from COVID-19

Abstract With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julian Varghese, Sarah Sandmann, Kevin Ochs, Inga-Marie Schrempf, Christopher Frömmel, Martin Dugas, Hartmut H. Schmidt, Richard Vollenberg, Phil-Robin Tepasse
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/703ad36a63994d60b41376313a839ce5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:703ad36a63994d60b41376313a839ce5
record_format	dspace
spelling	oai:doaj.org-article:703ad36a63994d60b41376313a839ce52021-12-02T16:04:18ZPersistent symptoms and lab abnormalities in patients who recovered from COVID-1910.1038/s41598-021-91270-82045-2322https://doaj.org/article/703ad36a63994d60b41376313a839ce52021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91270-8https://doaj.org/toc/2045-2322Abstract With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a university hospital for follow-up care and potential convalescent plasma donation. Network analysis was applied to visualize symptom combinations and persistent symptoms. Comprehensive lab-testing was ascertained at each follow-up to analyze differences regarding patients with vs without persistent symptoms. 116 patients were included, age range was 18–69 years (median: 41) with follow-ups ranging from 22 to 102 days. The three most frequent persistent symptoms were Fatigue (54%), Dyspnea (29%) and Anosmia (25%). Lymphopenia was present in 13 of 112 (12%) cases. Five of 35 cases (14%) had Lymphopenia in the later follow-up range of 80–102 days. Serum IgA concentration was the only lab parameter with significant difference between patients with vs without persistent symptoms with reduced serum IgA concentrations in the patient cohort of persistent symptoms (p = 0.0219). Moreover, subgroup analyses showed that patients with lymphopenia experienced more frequently persistent symptoms. In conclusion, lymphopenia persisted in a noticeable percentage of recovered patients. Patients with persistent symptoms had significantly lower serum IgA levels. Furthermore, our data provides evidence that lymphopenia is associated with persistence of COVID-19 symptoms.Julian VargheseSarah SandmannKevin OchsInga-Marie SchrempfChristopher FrömmelMartin DugasHartmut H. SchmidtRichard VollenbergPhil-Robin TepasseNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Julian Varghese Sarah Sandmann Kevin Ochs Inga-Marie Schrempf Christopher Frömmel Martin Dugas Hartmut H. Schmidt Richard Vollenberg Phil-Robin Tepasse Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
description	Abstract With increasing numbers of patients recovering from COVID-19, there is increasing evidence for persistent symptoms and the need for follow-up studies. This retrospective study included patients without comorbidities, who recovered from COVID-19 and attended an outpatient clinic at a university hospital for follow-up care and potential convalescent plasma donation. Network analysis was applied to visualize symptom combinations and persistent symptoms. Comprehensive lab-testing was ascertained at each follow-up to analyze differences regarding patients with vs without persistent symptoms. 116 patients were included, age range was 18–69 years (median: 41) with follow-ups ranging from 22 to 102 days. The three most frequent persistent symptoms were Fatigue (54%), Dyspnea (29%) and Anosmia (25%). Lymphopenia was present in 13 of 112 (12%) cases. Five of 35 cases (14%) had Lymphopenia in the later follow-up range of 80–102 days. Serum IgA concentration was the only lab parameter with significant difference between patients with vs without persistent symptoms with reduced serum IgA concentrations in the patient cohort of persistent symptoms (p = 0.0219). Moreover, subgroup analyses showed that patients with lymphopenia experienced more frequently persistent symptoms. In conclusion, lymphopenia persisted in a noticeable percentage of recovered patients. Patients with persistent symptoms had significantly lower serum IgA levels. Furthermore, our data provides evidence that lymphopenia is associated with persistence of COVID-19 symptoms.
format	article
author	Julian Varghese Sarah Sandmann Kevin Ochs Inga-Marie Schrempf Christopher Frömmel Martin Dugas Hartmut H. Schmidt Richard Vollenberg Phil-Robin Tepasse
author_facet	Julian Varghese Sarah Sandmann Kevin Ochs Inga-Marie Schrempf Christopher Frömmel Martin Dugas Hartmut H. Schmidt Richard Vollenberg Phil-Robin Tepasse
author_sort	Julian Varghese
title	Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
title_short	Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
title_full	Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
title_fullStr	Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
title_full_unstemmed	Persistent symptoms and lab abnormalities in patients who recovered from COVID-19
title_sort	persistent symptoms and lab abnormalities in patients who recovered from covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/703ad36a63994d60b41376313a839ce5
work_keys_str_mv	AT julianvarghese persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT sarahsandmann persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT kevinochs persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT ingamarieschrempf persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT christopherfrommel persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT martindugas persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT hartmuthschmidt persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT richardvollenberg persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19 AT philrobintepasse persistentsymptomsandlababnormalitiesinpatientswhorecoveredfromcovid19
_version_	1718385279010603008

Persistent symptoms and lab abnormalities in patients who recovered from COVID-19

Ejemplares similares